Asset Details
Do you wish to reserve the book?
Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice
Do you wish to request the book?
Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Suppressive effects of the sodium-glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice
2019
Overview
Sodium-glucose cotransporter 2 inhibitors were developed for the treatment of diabetes mellitus. Although recent studies have indicated that sodium-glucose cotransporter 2 inhibitors have suppressive effects on several types of cancer, their effects against colorectal cancer remain unknown. The purpose of the present study was to investigate the effects of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, on the development of colorectal cancer in diabetic and obese mice. The direct effects of tofogliflozin on the proliferation of colorectal cancer cells were also evaluated. C57BL/KsJ-db/db mice were injected with azoxymethane to induce colorectal pre-malignancy and they received drinking water with or without tofogliflozin. At the end of the study, administration of tofogliflozin was revealed to significantly suppress the development of colorectal neoplastic lesions and β-catenin accumulated crypts. In the tofogliflozin-treated mice, the levels of blood glucose and serum TNF-α, as well as mRNA expression of the pro-inflammatory markers in the white adipose tissue, were reduced. Furthermore, macrophage infiltrations in the white adipose tissues were also reduced significantly. The proliferation of the sodium-glucose cotransporter 2-expressing human colorectal cancer cells was not altered by tofogliflozin. These results indicated that tofogliflozin ameliorated chronic inflammation and hyperglycemic condition leading to prevention of colorectal tumorigenesis in a diabetes- and obesity-related colorectal cancer model.
Publisher
D.A. Spandidos,Spandidos Publications,Spandidos Publications UK Ltd
Subject
/ Analysis
/ Animals
/ Benzhydryl Compounds - pharmacology
/ Blood Glucose - drug effects
/ Carcinogenesis - drug effects
/ Cell Proliferation - drug effects
/ Colorectal Neoplasms - chemically induced
/ Colorectal Neoplasms - drug therapy
/ Colorectal Neoplasms - genetics
/ Colorectal Neoplasms - pathology
/ Diabetes
/ Diabetes Mellitus, Type 2 - drug therapy
/ Diabetes Mellitus, Type 2 - genetics
/ Gene Expression Regulation, Neoplastic - drug effects
/ Glucose
/ Humans
/ Hypoglycemic Agents - pharmacology
/ Insulin
/ Mice
/ Obesity
/ RNA
/ Sodium-Glucose Transporter 2 - genetics
/ Sodium-Glucose Transporter 2 Inhibitors - pharmacology
/ Studies
/ Tumor Necrosis Factor-alpha - genetics
/ Tumors
/ Water
